SCHEMBL2949912

SCHEMBL2949912

Cc1ccc(NC(=O)c2oc3cccnc3c2NC(=O)C2CCC(N3CCOCC3=O)CC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42
▸ SENP6 Q9GZR1 1/20 0.42
▸ LMNA P02545 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ NPY5R Q15761 6/20 0.39
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.37
▸ WNT3 P56703 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949907 1.00 MAPK1 (0.46) MAPK1ALOX15NPC1RAB9AKMT2A
SCHEMBL2947431 0.91 F10 (0.41) MAPK1NPC1RAB9AKMT2AALDH1A1
SCHEMBL2947435 0.91 F10 (0.41) MAPK1NPC1RAB9AKMT2AALDH1A1
SCHEMBL13290607 0.91 NPY5R (0.44) NPC1RAB9AKMT2AALDH1A1TSHR
SCHEMBL13290611 0.90 KMT2A (0.44) MAPK1ALOX15NPC1RAB9AKMT2A
SCHEMBL2953860 0.90 MAPT (0.49) ALOX15NPC1RAB9AKMT2ALMNA
SCHEMBL2953862 0.90 MAPT (0.49) ALOX15NPC1RAB9AKMT2ALMNA
SCHEMBL13299112 0.90 NPY5R (0.38) MAPK1ALOX15NPC1RAB9AKMT2A
SCHEMBL13290932 0.89 NPY5R (0.41) MAPK1ALOX15NPC1RAB9AKMT2A
SCHEMBL13290695 0.88 NPY5R (0.39) MAPK1ALOX15NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 MAPK1 3423/4885ALOX15 122/4885NPC1 4426/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 MAPK1 3611/4885ALOX15 177/4885NPC1 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback